Mood Disorder Treatment Market: IntroductionMood disorder, also known as affective disorder, is a mental health issue characterized by a serious change in mood that affects the person’s daily lifeThere are various types and subtypes of mood disorder; however, it can be segmented into three major states: depressive, manic, and bipolarMood disorder is a broad term that's used to include all types of depressive and bipolar disordersIf someone has symptoms of a mood disorder, the moods may range from extremely low (depressed) to extremely high or irritable (manic).
This primarily affects the person’s emotional state.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=79447 Key Drivers and Restrains of Global Mood Disorder Treatment MarketMajor players are focused on research & development of new drugs for the treatment of mental illness.
received the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) of VRAYLAR (cariprazine), for the use and treatment of depressive episodes associated with bipolar I disorder in adults.Rise in partnerships, collaborations, and agreements between companies and/or research institutes for the development, marketing, and distribution of mood disorder treatment is anticipated to drive the global mood disorder treatment market.
For instance, Sumitomo Dainippon Pharma and Angelini announced a partnership for commercialization of Latuda (Lurasidone Hydrochloride) in November 2017 for Europe.Request COVID Analysis on Mood Disorder Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=79447 As per World Health Organization (WHO), depression is expected to be the leading burden of disease worldwide by 2030.
Increasing prevalence of mood disorder is anticipated to drive the global mood disorder treatment market.Rise in government driven initiatives in the field of mood disorder treatment is projected to fuel the global market during the forecast period.
For instance, in February 2020, India and the U.S. signed an agreement on mental health, which is projected to enable India to learn from the experience of the U.S. in the treatment of mental health issues and is likely to facilitate greater access to traditional Indian medicines and therapies to treat mental health challenges in the U.S.Several drugs used in mood disorder have numerous side-effects such as addiction, blurred vision, damage to liver & thyroid, impaired memory, and tremors.